Objective: Trans-apical aortic valve implantation (TA-AVI) has been shown to be a reproducible technique. Early results from the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry identified major access complications associated with high 30-day mortality. Using the SOURCE Registry, we analyze the learning curve for TA-AVI over the first 2 years after commercialization. Methods: The SOURCE Registry gathered data for 2 consecutive years at European centers following commercialization of the Edwards SAPIEN TM bioprosthesis, totaling 2339 patients (1038 in COHORT 1 and 1301 in COHORT 2). Only data from centers that provided all of their consecutively treated patients were included in this study. We compared the 30-day results of TA-AVI from COHORT 1 (C-
Introduction
Trans-catheter aortic valve implantation (TAVI) is an established treatment option for aortic stenosis (AS) in patients seen as high risk for aortic valve replacement (AVR) [1] [2] [3] [4] [5] . The trans-apical approach (TA-AVI) has been used in clinical trials since 2004, to establish a technique that is not dependent on vascular access. As a result, the Edwards SAPIEN TM bioprosthesis was developed and received CE-Mark certification in January 2008. It is currently the only commercially available device for this procedure, and, since 2004, more than 5000 TA-AVIs have been implanted worldwide.
Single centers have published encouraging early results involving this technique with 30-day mortalities lower than predicted for AVR [2, 3, 6, 4] . Analyses of COHORT 1 (C-1) from the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry based on 575 consecutive patients, who underwent TA-AVI, identified risk factors for 30-day mortality, which were published previously in this journal [7] . These data also showed that intra-operative vascular/access complications and conversion to open surgery during TA-AVI carried a more than 50% perioperative mortality risk [7] . Having this in mind, it can be hypothesized that, with increasing experience in patient selection and operative technique, perioperative results may improve.
The number of TAVI procedures, in general, is constantly rising, and, worldwide, a total of more than 10 000 procedures have been performed. However, little is known about changes of co-morbidities for TAVI due to inclusion criteria, the technical learning curve of the procedure and how patient outcomes have changed over time.
In this article, we present the 30-day results for TA-AVI from the SOURCE Registry and compare outcomes of C-1 (January 2008-January 2009) with the more recently treated COHORT 2 (C-2) (February 2009-December 2009).
Materials and methods

Registry
The SOURCE Registry is currently the largest and most comprehensive data set involving the experience with the Edwards SAPIEN TM trans-catheter heart valve in Europe, totaling 2339 patients (1038 in C-1 and 1301 in C-2) treated in 36 centers from 13 countries ( Table 1 ). The Registry's methodology, as well as inclusion criteria for patients and centers, procedures and devices, training and proctoring for the procedures, definitions and data collection have been described previously [1] . All patients in this study were treated using the Ascendra TM Introducer sheath to implant a 23-mm or 26-mm Edwards SAPIEN TM trans-catheter heart valve. C-2 is the group of patients treated between February 2009 and December 2009. As in C-1, to produce a scientifically robust data set, only centers that could provide data on 100% of their consecutively treated patients during this time were used for the present analysis. A total of 1301 patients were treated in C-2, 819 (63.0%) of whom received TAVI using the trans-apical approach. C-2 was performed at 39 centers, 32 of which were already included in C-1. There were an additional nine centers, which started their experience while data for C-2 was collected, and two centers that were in C-1 chose not participate in C-2. At these nine centers, which were new to the SOURCE Registry, a total of 122 patients (14.9% of C-2) underwent TAVI.
Purpose of this study
In this article, we compare the 30-day results from TA-AVI in C-1 (n = 575) of the SOURCE Registry to C-2 (n = 819), which comprised patients who underwent TA-AVI during the second year after commercialization. Using detailed analyses of patient demographic and risk variables, we investigate changes in indication for TA-AVI treatment and its impact on the 30-day results. We also answer the questions if TA-AVI has a learning curve and if intra-operative complications are now reduced compared with previous outcomes. In addition, univariate and multivariate analyses on the combined patient group (n = 1394) are presented to identify predictors for 30-day mortality after TA-AVI.
Definitions and data collection
Definitions and the methodology of data collection in the SOURCE Registry were reported previously [1] .
For the total group of patients from C-1, the completeness of procedural data is now 100%, 30-day data 99.9% (98.0% C-2) and 1-year data 98.0% (C-1 only). The 30-day follow-up percentage is slightly higher compared with the original report when it was 98%, and this has resulted in minor variations of the baseline demographic data in C-1 being reported in this publication compared with the original [1] ; however, this is not of any clinical significance.
Events and values collected are site reported and there are no core laboratories. The principal investigators (OW and MRT) reviewed and adjudicated all clinical and adverse events reported into the Medidata RAVE electronic database 
Statistical analysis
Continuous variables are presented as mean AE standard deviation (SD) and were compared between groups using the two-sample t-test. Categorical variables are given as frequencies and percentages, and were compared using Fisher's exact test. All statistical analyses were performed using SAS, version 9.2 (SAS Institute Inc, Cary, NC, USA).
Thirty-day survival is based on days subsequent to the valve implant without consideration of discharge from the hospital. The proportion of patients censored prior to 30 days is less than 1%, and pure proportion and Kaplan- The missing data pattern for ejection fraction presented a special challenge, as missing ejection fraction was significantly correlated with 30-day death. Details are provided in Section 3.
Results
Demographics and baseline data
Demographic and baseline characteristics are shown in Table 2 . The mean logistic EuroSCORE was 28.0%, and was not significantly different between C-1 (29.1%) and C-2 (27.3%). The risk profile of the patients remains high with the most important co-morbidities being, coronary artery disease (56.0%), concomitant mitral valve disease (36.2%), renal dysfunction (31.2%), congestive heart failure (28.2%), diabetes mellitus (27.8%), previous coronary artery bypass grafting (27%), previous percutaneous coronary intervention (26.8%), peripheral vascular disease (26.4%), pulmonary disease (26.0%), carotid artery stenosis (15.4%), and porcelain aorta (10.2%).
Comparing C-1 to C-2 (Table 3) , a statistically significant increase of patients with concomitant mitral valve disease (32.0% vs 39.2%) and congestive heart failure (24.4% vs 30.9%) was observed over time. By contrast, patients in C-2 presented less frequently with insulin-dependent diabetes (10.0% vs 14.1%) and pulmonary disease (23.3% vs 29.9%).
The number of patients with a EuroSCORE of <20% significantly increased over time (C-1: 29.6% vs C-2: 39.6%, p = 0.0001). Comparison between demographic variables among patients with EuroSCORE of !20% shows that 'porcelain aorta' (62/494 or 12.6% vs 79/898 or 8.8%, p = 0.0323) and 'cancer' (89/170 or 18.02% vs 110/898 or 8.8%, p = 0.0039) were the only two variables more often found in the lower risk group. Over time, clinical and statistically significant changes in the demographic profile of lower EuroSCORE patients were only identified by 'congestive heart failure', which increased from 14.1% in C-1 (24/170) to 27.8% in C-2 (90/324, p = 0.0007), and 'mitral valve disease', which increased from 25.9% (C-1: 44/170) to 39.8% (C-2: 129/ 324, p = 0.0028).
Operative data
Operative data are provided in Table 4 . The placement of an Edwards SAPIEN TM valve inside an Edwards SAPIEN TM valve occurred in 21 C-1 patients (3.7%) and 20 C-2 patients (2.44%) ( p = ns), resulting in a total of 596 Edwards SAPIEN TM valves implanted in C-1 and 839 in C-2. The incidences of malposition (1.6% vs 1.2%), valve embolization/migration (0.5% vs 1.0%), and coronary obstruction (0.7% vs 0.2%) were not statistically significant. However, the number of cases, which led to conversion to open-heart surgery decreased over time (C-1: 3.7%, C-2 1.5%, p = 0.0315). In addition, aortic regurgitation > grade 2+ at the end of the procedure was less frequent in C-2 (2.1%) compared with C-1 (4.5%, p = 0.0014).
Postoperative complications
Major postoperative complications are shown in Table 5 . The overall 30-day mortality was 10.8%, and revealed no significant difference between the two cohorts (C-1: 10.8 vs C-2: 10.7). Overall, the majority of all deaths < 30 days was caused by multi-organ failure (30/150, 20.0%) and heart failure (30/150, 20.0%).
A permanent pacemaker was implanted in a total of 7.1% with no significant change over time. The incidence of vascular complications remained low, specifically, 1.8% in C-2 compared with 2.1% in C-1 ( p = ns). In C-1, there was one case each of aortic dissection, apical rupture, left ventricular tear and apical bleeding. In C-2, only two apical complications, that is, one apical rupture and one apical perforation resulted in a 30-day death. Although the incidence of renal failure requiring dialysis was lower in C-2 (5.7%) compared with C-1 (7.0%), this does not reach statistical significance.
Postoperative stay in the intensive care unit is reduced now with a median of 1 day in C-2 (range 0-53) compared with two days in C-1 (range 0-89) ( p = 0.0315).
Univariate analysis
Based on the total cohort of patients (n = 1394) and according to our previous publication [7] , various baseline factors were considered to develop models to predict 30-day mortality (Table 6 ). EuroSCORE ! 30% ( p = 0.0001) and ejection fraction < 30% or not measurable ( p = 0.0007) remained significant predictors, and the significance of the findings has increased compared with C-1 alone.
The only previously identified risk factor, carotid artery stenosis, which interestingly predicted a lower 30-day mortality, was found not to have any predictive value for 30-day mortality in the larger cohort ( p = 0.1728).
In addition, the larger cohort identified EuroSCORE ! 20% ( p = 0.0037), renal insufficiency/failure ( p = 0.0001), ejection fraction < 30% ( p = 0.0158), and an Edwards SAPIEN TM prosthesis size 23 mm ( p = 0.0253) as predictors of 30-day mortality.
Three continuous risk factors (age, EuroSCORE and ejection fraction) were considered (Table 7) . To more easily interpret the odds ratios, the parameters were divided by 10. This scaling did not impact the p-values. In the previous publication [7] , the scaled left ventricular ejection fraction and scaled EuroSCORE were significant predictors for 30-day mortality. In the combined cohort, they are now even more so ( p = 0.0066). The fact that 'missing ejection fraction', in itself, is no longer a predictive risk factor renders these results statistically even stronger.
Multivariate analysis
Various baseline values were included in a multivariable logistic regression (Table 8 ). Due to the high correlation among the various variables, the forward selection and backward elimination methods did not provide useful models. The score selection model identified Euro-SCORE ! 30% and renal insufficiency/failure as the only significant predictors for 30-day mortality.
Discussion
AVR is the treatment of choice in patients with AS and is superior to medical treatment [8] . However, it is well known that not all patients with significant AS undergo AVR [9] . This is partly because they are not referred for surgery, they personally decline surgery or they are turned down by a surgeon due to their high risk for AVR [8] . Given that untreated AS has a very poor outcome after symptoms appear, TAVI was developed as a treatment option particularly for this group of patients. Most of these patients are elderly and have very high risk or were denied AVR, and would therefore benefit most from a less traumatic interventional/ surgical technique.
The Corevalve TM and the Edwards SAPIEN TM bioprostheses are, currently, the only two prostheses commercially available for TAVI, and their design and technical differences have been described previously [10] [11] [12] . Both are approved for implantation using the transfemoral (TF-AVI) approach. However, a significant number of these elderly patients are quite small or present co-morbidities, which make cannulation and/or passage of the femoroiliac arteries or aorta impossible. Access issues do not play a role in TA-AVI and, therefore, it can be technically performed in almost all patients as long as the left ventricular apex is free of disease [11] . TA-AVI is currently only approved in Europe using the Edwards SAPIEN TM valve and the Ascendra TM delivery system. Although the vast majority of TAVIs are currently performed using a transfemoral or trans-apical approach, alternative techniques with limited experience have been described previously. Access through the subclavian artery is feasible, but again, is limited by size and quality of the artery itself [13, 14] . In addition, a patent internal thoracic artery bypass graft is currently regarded as a relative contraindication for this approach after acute dissections of the subclavian artery with graft closure have been observed. A direct transaortic approach has also been reported, but because it requires a limited sternotomy, it carries its own perioperative risk and is only suitable in patients with excellent wall quality of the ascending aorta [15] . The SOURCE Registry was initiated to assess the clinical experience in Europe after commercialization of the Edwards SAPIEN TM bioprosthesis [1] . As a result of the strict adherence to consecutive patient enrolment, it now represents the world's largest and most comprehensive data set on TAVI (n = 2339) with a total of 1394 TA-AVI patients in C-1 and C-2. As presented, the 30-day mortality of the entire cohort is 10.8%, which is similar to single-center experiences, where 30-day mortalities of 8.3-16.9% have been reported [2] [3] [4] [5] .
Given that Walther et al. described a learning curve for TA-AVI [2] , it is surprising that 30-day mortality between C-1 (10.8%) and C-2 (10.7%) was not significantly different. This may be explained by the fact that the very early experience from Leipzig [2] represented the first worldwide operations and, therefore, an early learning curve was unavoidable. Centers, which started TA-AVI during commercialization, went through a strict training and proctoring program based on the experience of these centers [1] and, therefore, may have experienced less of a learning curve. It is worth mentioning that although 30-day mortality has not improved over time, technical complications resulting in conversion to AVR and incidence of severe aortic regurgitation (AR) after valve implantation have significantly decreased, which may reflect a learning curve in itself. This may not have resulted in improved 30-day survival because the logistic EuroSCORE of C-2 remained high, and was not significantly different from C-1; therefore, the postoperative mortality may be more a result of co-morbidities than intra-operative technical complications.
The univariate and multivariate analyses on the entire patient cohort are presented to identify additional predictors for 30-day mortality after TA-AVI, and the results of the larger cohort have strengthened our previous findings that a higher EuroSCORE and impaired left ventricular function are risk factors for 30-day mortality. Clinically, it is not surprising that renal disease in the larger cohort is now also identified as a predictor of 30-day mortality, and even became significant in the multivariate model.
However, 1-year survival is, of course, more important for patients and also for determining the cost-effectiveness of TAVI treatment. For C-1, a 1-year survival of 72.1% has been recently presented by our group [16] . In this context, it is important to note that the 30-day mortality counts only for approximately one-third of the 27.9% mortality. Knowing that the majority of late deaths are due to non-cardiac causes, it becomes clear that co-morbidities again play, as for 30-day mortality, an important role. It, therefore, is questionable if we are currently measuring and collecting the appropriate predictive baseline risk factor information required to predict TAVI patient outcomes. It seems that we also need, at a minimum, a form of frailty score or a functional test, such as a 6-min walk test, to place the demographic variables in context.
Echocardiographic performance of the Edwards SAPIEN TM trans-catheter heart valve (THV) was reportedly excellent [17] , and prosthetic failure after TAVI is currently rare. However, one case of endocarditis was reported 2 months after TA-AVI using an Edwards SAPIEN TM THV [18] , and a failing Corevalve TM prosthesis was found 4 months after TF-AVI [19] . It remains to be seen how these valves will perform over the long term.
The results of the prospective randomized Placement of AoRtic TraNscathetER Valve (PARTNER) US trial will soon show us how TF-AVI using the Edwards SAPIEN TM THV directly compares with AVR. However, another question which remains unanswered is how TA-AVI compares with TF-AVI. Currently, there are no prospective randomized studies available. Previously reported 30-day data from the SOURCE Registry showed a slightly higher mortality for TA-AVI (10.3%) compared with TF-AVI (6.3%), but the TA-AVI group showed significantly more co-morbidities, and a direct comparison of the two groups was therefore not feasible [1] . Reports from the Canadian Experience show no difference between the two groups with 30-day survival of 9.5% (TF-AVI) versus 11.3% (TA-AVI) [5] . A German group even reports a lower mortality after TA-AVI (8.3%) compared with TF-AVI (11.2%) [4] . Interestingly, the 1-year mortality in the SOURCE Registry in patients with EuroSCOREs < 20% is not significantly different between TF-AVI (19.1%) and TA-AVI (21.6%), although demographic risk factors were still more frequently noted in the TA-AVI group [16] . Only prospective randomized investigations involving patients suitable for both approaches will give the answer as to how the two approaches compare with each other.
For the future, it is promising that we now have the next generation of the Edwards SAPIEN TM THVs available, which are suitable for TA-AVI. The Edwards SAPIEN XT TM valve and Ascendra 2 TM delivery system recently received CE-Mark certification, and will hopefully make implantation of the device even more feasible. It will also be interesting to see what impact new indications, such as the treatment of a failing bioprosthesis, will have on numbers and outcomes of TA-AVI [20] .
In conclusion, TA-AVI was successfully introduced into medical practice and produces excellent short-term results. Reduction of technical complications during implantation has resulted in reduced conversion to conventional surgery and perioperative AR, reflecting the learning curve. However, the 30-day mortality is not affected making it most likely a result of patient co-morbidities. TA-AVI is an alternative type of treatment in patients with high risk for AVR; however, its long-term results remain to be determined.
Limitations of the SOURCE Registry
The SOURCE Registry is a clinical registry and contains limited functional assessment of the Edwards SAPIEN TM valve. In addition, all adverse events were self-reported by the participating centers; no adjudication of adverse events via source documentation was assessed.
However, review and adjudication of all serious adverse events and adverse events in the electronic database was performed by the principal investigators.
Appendix A. Conference discussion Dr J. Pepper (London, UK): This is an audit of prospectively collected data on 1394 patients out of a total of 2339. Actually since the abstract was published, your cohorts changed slightly. So the 2008/9 cohort is now 575 compared with the 2009/10 cohort, which is 819. Although this appears to be a learning curve, it could be that more centers were recruited in the second time frame, and it would be helpful if you would clarify that, and it might explain why the mortality of 10.8% is unchanged through the study. And do you actually know the cause of death in each case? This is a paper which tends to concentrate mainly on the technical aspects with very little information on ventricular performance and, given that the ejection fraction data was incomplete, was there a uniform method of measurement and, if so, what was it? Did you look at LV mass in a consistent manner and, if so, what was the mean and range of the preoperative LV mass? And given that the mean ejection fraction was 32% (and in fact only 4.5% had an ejection fraction of less than 30%), it would seem that left ventricular function was only moderately impaired in most patients, and so the driving force for the transcutaneous approach was the age of the patient and the comorbidity.
There doesn't seem to be any catheterization data, and yet I suspect this was carried out in most centers, and I wondered if you had any data on that.
And a very last point. Would you agree that the logistic EuroSCORE in its present form is not as helpful as it could be in predicting risk for this procedure?
Dr Wendler: I would like to divide your comments into two main questions. First how much data we have on left ventricular function, how much data we have on hemodynamics in general, how much data we have on the results from the angiogram and so on.
The point I need to stress is this is a registry. That means at the moment we ask for something like 35 preoperative variables. In addition, there are all the postoperative data. The complete data set is something like six or seven pages long. An additional problem is that we don't have core lab assistance for echo data, we don't have a core lab for angiography data or ejection fraction. So it is a self-reporting registry for that purpose. That is the reason why we don't report in detail on the echo data. We have echo data, but we are not feeling confident enough that this echo data is really accurate enough to be presented. We report on the AR 2+ because we get the impression that it is most likely to be accurate. But what you all know is if you have controlled trials, there is sometimes quite a variance between the core lab and what the centers report themselves, and I think we just have to realize that this is a limitation of the SOURCE registry.
There is another aspect of questions you asked, and that is about the EuroSCORE itself. What I personally believe is that EuroSCORE gives an idea about a general risk profile of a patient. What is very clear is that it is not reflecting appropriately the absolute risk for surgery or TAVI's in terms of the figure of the EuroSCORE calculation. Nevertheless, what we know from conventional surgery, what has been shown in TAVI, and what we also know from the UK registry, is that the EuroSCORE is an excellent predictor of the relative patient risk. The absolute risk may be only a third of what we have calculated and then coming close to the STS score, but as for conventional surgery, it is a prediction of risk. We know from the UK registry that very high EuroSCOREs are a predictor of adverse events of inferior outcome. That is the reason why I think the fact that we found that more than 30% EuroSCORE is a predictor of 30-day mortality, from my point of view nicely fits together with what we, for example, know from the UK registry.
The other aspect one should not forget is that we have shown that there is not a big learning curve.
Dr Pepper: Were the contributors to cohort 1 the same as the contributors to cohort 2? Dr Wendler: Sorry, I forgot that question. All the centers who contributed to cohort 1 contributed to cohort 2 as well. There were nine new centers. That was the reason why we made the calculation on the centers who had an experience in the past from the first year. Have they produced better results in the second year? That was not a statistically significant difference. We also compared the total group of centers who had experience with the total group of centers who had no experience at the start of cohort 2. There was again no difference seen.
What I think this shows, and maybe it goes a little bit in the direction of what we heard about the Berlin data, is that the way the technique is introduced, with quite a rigorous type of training program, which ends up with proctoring on site for the first implantation, may be the reason why the technical aspects play less of a role for the 30-day outcome.
What I would like to add is that one also needs to recognize that all the technical complications result in a 30-day mortality which is usually around 50%. But the absolute number of these complications is so low that, in the end, they don't play such a big role for the 30-day outcome.
But to just add one thing, we have identified this as a weakness of the registry. That is the reason why now in the next generation of the SOURCE registry we will have a frailty score, an exercise test, and a subgroup of centers who have a particular interest in the echo data, performing echo sub-studies. We then will hopefully be able to address certain questions more accurately than at the moment, and I am afraid that this has also been a learning process for ourselves.
Dr N. Moat (London, UK): Just very briefly to come back to these data, why do you think we are not taking on more patients with low ejection fraction? You have very experienced centers, 4.9% less than 30%. Why are all of us not taking on more of these low ejection fraction patients? What do you think is happening?
Dr Wendler: Well, I think if you look at the whole group of patients with aortic stenosis, there are just not too many with a low ejection fraction. And the other thing is that I think the ones who have aortic stenosis and low ejection fractions tend to be younger. So is that the reason why we have less of them? I don't know. But if you look into series of conventional aortic valve surgery, the number of patients with low ejection fraction is usually not very high. There are usually around 8-9% of patients with low ejection fraction in these series, across the whole age range of patients. So that is the reason why I am not surprised that there are not so many patients with low ejection fraction in the SOURCE registry.
